metricas
covid
Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology Prevalence of non alcoholic fatty liver disease and associated factors?
Información de la revista
Vol. 27. Núm. 2.
(marzo - abril 2022)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 27. Núm. 2.
(marzo - abril 2022)
Open Access
Prevalence of non alcoholic fatty liver disease and associated factors?
Visitas
632
Segundo Moran
Este artículo ha recibido

Under a Creative Commons license
Información del artículo
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Texto completo

In regard to the article by Denova et al. [1], it should be highlighted that, based on the liver function tests together with other biochemical tests and anthropometric values, several indices are generated and are used for the non-invasive diagnosis of non-alcoholic fatty liver disease (NAFLD) [2]. However, it should be mandatory in every study to exclude subjects with an excessive alcohol consumption and previous liver diseases such as chronic infection with hepatitis B or C viruses [3–5]. Therefore, attention is called to the fact that in this study, Denova et al. refer that “the prevalence of NAFLD was 53.2%”, but at the same time 54% of the participants included in the analysis consumed alcohol and, furthermore, other frequent causes of hepatic function test alterations were not excluded. The lack of consistency of factors such as the low socioeconomic status found in the study by Denova et al. compared to those studies performed worldwide may be also related to a sample selection bias for the diagnosis of NAFLD. Therefore the authors should adjust their results and conclusion accordingly to the aforementioned considerations.

References
[1]
E Denova-Gutierrez, L Lara-Castor, C Hernández-Alcaraz, M Hernández-Avila, C Aguilar-Salinas, D Kershenobich, et al.
Prevalence and predictors of elevated liver enzyme levels in Mexico: the Mexican National Health and Nutrition Survey, 2016.
[2]
JH Zhou, JJ Cai, ZG She, HL. Li.
Noninvasive evaluation of nonalcoholic fatty liver disease: current evidence and practice.
World J Gastroenterol, 25 (2019), pp. 1307-1326
[3]
European Association for the Study of the Liver, European Association for the Study of Diabetes, European Association for the Study of Obesity. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease.
J Hepatol, 64 (2016), pp. 1388-1402
[4]
N Chalasani, Z Younossi, JE Lavine, M Charlton, K Cusi, M Rinella, et al.
The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases.
Hepatology, 67 (2018), pp. 328-357
[5]
VW Wong, WK Chan, S Chitturi, Y Chawla, YY Dan, A Duseja, et al.
Asia-pacific working party on non-alcoholic fatty liver disease guidelines 2017: part 1—definition, risk factors and assessment.
J Gastroenterol Hepatol, 33 (2018), pp. 70-85
Copyright © 2022. Fundación Clínica Médica Sur, A.C.
Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos